HK1151694A1 - Fused bicyclic pyrimidine compounds as aurora kinase inhibitors - Google Patents

Fused bicyclic pyrimidine compounds as aurora kinase inhibitors

Info

Publication number
HK1151694A1
HK1151694A1 HK11105941.6A HK11105941A HK1151694A1 HK 1151694 A1 HK1151694 A1 HK 1151694A1 HK 11105941 A HK11105941 A HK 11105941A HK 1151694 A1 HK1151694 A1 HK 1151694A1
Authority
HK
Hong Kong
Prior art keywords
kinase inhibitors
fused bicyclic
aurora kinase
pyrimidine compounds
bicyclic pyrimidine
Prior art date
Application number
HK11105941.6A
Other languages
English (en)
Chinese (zh)
Inventor
謝興邦
‧考瑪
徐祖安
伍素螢
趙宇生
Original Assignee
國家衛生研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 國家衛生研究院 filed Critical 國家衛生研究院
Publication of HK1151694A1 publication Critical patent/HK1151694A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK11105941.6A 2008-04-30 2011-06-13 Fused bicyclic pyrimidine compounds as aurora kinase inhibitors HK1151694A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4906308P 2008-04-30 2008-04-30
PCT/US2009/041382 WO2009134658A2 (fr) 2008-04-30 2009-04-22 Composés de pyrimidine bicycliques fusionnés en tant qu'inhibiteurs d'aurora kinase

Publications (1)

Publication Number Publication Date
HK1151694A1 true HK1151694A1 (en) 2012-02-10

Family

ID=41255689

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11105941.6A HK1151694A1 (en) 2008-04-30 2011-06-13 Fused bicyclic pyrimidine compounds as aurora kinase inhibitors

Country Status (13)

Country Link
US (1) US8138194B2 (fr)
EP (1) EP2276346B1 (fr)
JP (1) JP5502072B2 (fr)
KR (1) KR101667822B1 (fr)
CN (1) CN102014627B (fr)
AU (1) AU2009241469B2 (fr)
CA (1) CA2722220C (fr)
DK (1) DK2276346T3 (fr)
ES (1) ES2616255T3 (fr)
HK (1) HK1151694A1 (fr)
PL (1) PL2276346T3 (fr)
TW (1) TWI363627B (fr)
WO (1) WO2009134658A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012130929A (ru) * 2009-12-23 2014-01-27 Байокрист Фармасьютикалз, Инк. Гетероциклические соединения в качестве ингибиторов янус-киназы
AU2010339444A1 (en) 2009-12-30 2012-07-19 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
TW201307347A (zh) 2010-11-01 2013-02-16 Arqule Inc 經取代苯並－咪唑並－吡啶並－二氮呯化合物
SG11201406185WA (en) * 2012-03-30 2014-11-27 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
JP2015518842A (ja) 2012-05-21 2015-07-06 バイエル ファーマ アクチエンゲゼルシャフト 置換ピロロピリミジン
EP2852596B1 (fr) 2012-05-21 2016-06-22 Bayer Pharma Aktiengesellschaft Thienopyrimidines
WO2013174735A1 (fr) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Benzothienopyrimidines substituées
AP3902A (en) 2012-06-29 2016-11-17 Pfizer Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
CN103664993B (zh) * 2012-09-25 2016-05-25 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
EP2951187A1 (fr) 2013-02-01 2015-12-09 Bayer Pharma Aktiengesellschaft Thiénopyrimidines substituées et leur utilisation pharmaceutique
CN105308054B (zh) 2013-03-06 2017-11-21 拜耳制药股份公司 取代的噻唑并嘧啶
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
TN2016000452A1 (en) 2014-04-25 2018-04-04 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands.
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN105061461B (zh) * 2015-08-18 2017-06-30 沈阳药科大学 含有苄胺结构的四氢苯并[4,5]噻吩并[2,3‑d]嘧啶类化合物及其应用
CN105061460B (zh) * 2015-08-18 2017-06-30 沈阳药科大学 含有硫醚结构的四氢苯并[4,5]噻吩并[2,3‑d]嘧啶类化合物及其应用
MX2018003215A (es) 2015-09-14 2018-06-08 Pfizer Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN106243124B (zh) * 2016-07-29 2018-03-09 湖北民族学院 一种噻吩并嘧啶脲类化合物及其制备方法和应用
US11020398B2 (en) 2016-08-24 2021-06-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
CN106810512B (zh) * 2017-01-18 2019-09-10 江苏省中医药研究院 Idh2突变体抑制剂及其用途
SG10202106345VA (en) * 2017-08-15 2021-07-29 Abbvie Inc Macrocyclic mcl-1 inhibitors and methods of use
UY37844A (es) * 2017-08-15 2019-03-29 Abbvie Inc Inhibidores de mcl-1 macrocíclicos y métodos de uso
CN112739343A (zh) * 2017-08-15 2021-04-30 艾伯维公司 大环mcl-1抑制剂和使用方法
CA3152021A1 (fr) * 2019-08-26 2021-03-04 Chemwerth, Inc. Composes (7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino substitues utiles comme inhibiteurs de jak1
CN112500421B (zh) * 2020-12-15 2021-08-24 河南科技大学第一附属医院 一种可用于杀菌消毒的苯并吡喃脲类化合物的制备方法及应用
WO2024039842A2 (fr) * 2022-08-19 2024-02-22 National Health Research Institutes Inhibiteurs de récepteurs tam

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008726A1 (de) * 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
DE60134679D1 (de) * 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
DE10141212A1 (de) 2001-08-22 2003-03-06 Bayer Ag Neue 4-Aminofuropyrimidine und ihre Verwendung
US7427623B2 (en) 2001-09-11 2008-09-23 Smithkline Beecham Corporation 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
US6814324B2 (en) * 2002-07-03 2004-11-09 Segway Systems, Llc Releasably latchable leader block in tape threading apparatus for data storage systems and method therefor
DE60315892T2 (de) 2002-12-24 2008-08-14 Astrazeneca Ab Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
SI1678166T1 (sl) * 2003-10-14 2009-10-31 Univ Arizona State Inhibitorji proteinske kinaze
US20050187389A1 (en) * 2004-01-13 2005-08-25 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
EA012112B1 (ru) 2004-05-14 2009-08-28 Миллениум Фармасьютикалз, Инк. Соединения и способы для ингибирования митотической прогрессии
JP2008505084A (ja) * 2004-06-29 2008-02-21 アムゲン インコーポレイティッド フラノピリミジン
WO2006003440A1 (fr) 2004-07-05 2006-01-12 Astex Therapeutics Limited Pyrazoles 3,4-disubstitutes servant d'inhibiteurs de kinases cyclines dependantes (cdk), ou de kinases aurora ou de glycogene syntases 3 (gsk-3)
CA2573999A1 (fr) * 2004-07-16 2006-04-06 Sunesis Pharmaceuticals, Inc. Thienopyrimidines utiles en tant qu'inhibiteurs des kinases aurora
CN101160316A (zh) * 2004-07-16 2008-04-09 苏内西斯医药公司 适合用作aurora激酶抑制剂的噻吩并嘧啶
EP1915377A1 (fr) * 2005-07-22 2008-04-30 Sunesis Pharmaceuticals, Inc. Pyrazolopyrimidines utiles comme inhibiteurs de la kinase aurora
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
ES2332423T3 (es) * 2005-10-28 2010-02-04 Irm Llc Compuestos y composiciones como inhibidores de proteina quinasas.
SI1962830T1 (sl) 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora

Also Published As

Publication number Publication date
EP2276346A4 (fr) 2011-08-24
KR101667822B1 (ko) 2016-10-19
CA2722220A1 (fr) 2009-11-05
DK2276346T3 (en) 2017-02-27
ES2616255T3 (es) 2017-06-12
AU2009241469B2 (en) 2015-05-07
CA2722220C (fr) 2016-06-07
US20090275533A1 (en) 2009-11-05
TW200948365A (en) 2009-12-01
KR20100132067A (ko) 2010-12-16
WO2009134658A3 (fr) 2009-12-30
JP2011522789A (ja) 2011-08-04
TWI363627B (en) 2012-05-11
CN102014627A (zh) 2011-04-13
CN102014627B (zh) 2014-10-29
PL2276346T3 (pl) 2017-07-31
JP5502072B2 (ja) 2014-05-28
EP2276346B1 (fr) 2016-11-23
US8138194B2 (en) 2012-03-20
WO2009134658A2 (fr) 2009-11-05
AU2009241469A1 (en) 2009-11-05
EP2276346A2 (fr) 2011-01-26

Similar Documents

Publication Publication Date Title
HK1151694A1 (en) Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
HK1217017A1 (zh) 作為激酶抑制劑的嘧啶取代的嘌呤化合物
ZA201101243B (en) Macrocyclics pyrimidines as aurora kinase inhibitors
HK1162509A1 (en) Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
ZA201100344B (en) Pyrimidine derivatives as kinase inhibitors
HK1220455A1 (zh) 嘧啶取代的大環抑制劑
IL218271A0 (en) Heterocyclic compounds as janus kinase inhibitors
HK1145496A1 (zh) 作為蛋白酪氨酸激酶抑制劑的雙環雜環化合物
PT2231642E (pt) Pirimidinas como inibidores de quinase
HK1145495A1 (zh) 作為蛋白酪氨酸激酶抑制劑的雙環雜環化合物
IL206358A0 (en) Pyrrolopyrazine kinase inhibitors
IL206818A0 (en) Pyrrolopyrazine kinase inhibitors
HK1161251A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
HK1146042A1 (en) Pyrimidine derivatives as protein kinase inhibitors
IL209931A0 (en) Bicyclic heterocycles as mek kinase inhibitors
IL210573A0 (en) Compounds as kinase inhibitors
IL215119A0 (en) Substitted fused pyrimidine compounds
HK1166984A1 (en) Fused pyrimidines as akt inhibitors akt
IL220205A0 (en) Heterocyclic compounds as janus kinase inhibitors
HK1215434A1 (zh) 取代的嘧啶衍生物
HK1156611A1 (en) Naphthyridininones as aurora kinase inhibitors aurora
ZA201106695B (en) Substituted fused pyrimidine compounds
ZA201104380B (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
ZA201004903B (en) Pyrrolopyrazine kinase inhibitors